4SC AG (VSC.F) Says Its Resminostat Meets Primary Endpoint In Phase II Trial  
1/19/2012 11:00:19 AM

(RTTNews) - 4SC AG (FSCGF.PK: News ) published encouraging efficacy data from the clinical Phase II SHELTER study with the cancer drug resminostat as a second-line therapy for patients with advanced liver cancer (hepatocellular carcinoma, HCC) who had exhibited radiologically proven tumour progression under first-line therapy with sorafenib prior to study entry.